SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival

Blood Adv. 2020 Nov 24;4(22):5716-5721. doi: 10.1182/bloodadvances.2020003345.

Authors

Kitsada Wudhikarn^{1

2}, Sanam Loghavi³, Abhishek A Mangaonkar¹, Aref Al-Kali¹, Moritz Binder¹, Ryan Carr¹, Kaaren Reichard⁴, Christy Finke¹, Matthew Howard⁴, Naseema Gangat¹, Ayalew Tefferi¹, Rami Komrokji⁵, Najla Ali⁴, Terra Lasho¹, Rhett Ketterling⁴, Eric Padron⁴, Mrinal M Patnaik¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
² Division of Hematology and Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, Thailand.
³ Division of Hematopathology, MD Anderson Cancer Center, Houston, TX.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and.
⁵ Malignant Hematology, Moffitt Cancer Center, Tampa, FL.

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myelomonocytic, Chronic*
Phosphoproteins
Prognosis
RNA Splicing Factors

Substances

Phosphoproteins
RNA Splicing Factors
SF3B1 protein, human